A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients
Rostami S, Alavi SM, Daghagheleh R, Maraghi E, Hosseini SA
Virology journal · 8 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2024-04-23 · Virol J · vol. 21 · número 1 · pág. 91
- Editorial
- BioMed Central
- Citado
- 7 citas · más que el 79% de estudios similares · 1.5× el promedio de su campo
- Referencias
- 54 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Long-Term Effects of COVID-19 · Sepsis Diagnosis and Treatment
- Palabras clave
- Medicine, Randomized controlled trial, Magnesium, Internal medicine, Oxygen saturation, Placebo, Clinical trial, Quality of life (healthcare), Oxygen therapy, Respiratory system, Gastroenterology, Oxygen, Nursing, Pathology
- MeSH
- humans, magnesium, tumor necrosis factor-alpha, c-reactive protein, treatment outcome, double-blind method, quality of life, dietary supplements, adolescent, adult, aged, middle aged, iran, female, male, young adult, covid-19, sars-cov-2, covid-19 drug treatment
5 autores
- Sepideh Rostami🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Seyed Mohammad Alavi🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Robab Daghagheleh🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Elham Maraghi🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Seyed Ahmad Hosseini🇮🇷 · autor de correspondenciaAhvaz Jundishapur University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
This study sought to examine the impact of magnesium supplementation on clinical outcomes and biochemical factors among hospitalized patients with COVID-19.
Methods
This double-blind, randomized clinical trial was conducted at Razi Hospital, Ahvaz, Iran, between September 2021 and March 2022. Participants aged 18-70 years with moderate disease severity were enrolled. Magnesium supplementation (300 mg daily) was administered to the intervention group, while the control group received a placebo. Clinical outcomes, including the need for oxygen therapy, oxygen saturation, respiratory rate, fever, hs-CRP and TNF-α levels, as well as quality of life and mental health, were assessed. Blood samples were collected to measure biochemical variables.
Results
The main result was the count of individuals requiring oxygen therapy. Additional outcomes comprised of oxygen saturation, respiratory rate, fever, hs-CRP and TNF-α levels, as well as quality of life and mental health. Out of 64 participants, 60 completed the study. The results showed that magnesium supplementation significantly reduced the number of patients requiring oxygen therapy (9 vs. 14; P 0.05).
Conclusion
The findings suggest that magnesium supplementation may have beneficial effects on clinical outcomes and arterial oxygen saturation in COVID-19 patients. More investigation is necessary to delve into its potential mechanisms and long-term effects on patient outcomes.
Trial registration
This study is registered on Iranian Registry of Clinical Trials (IRCT) under identifier IRCT20210413050957N1. (The registration date: May 1, 2021).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.